Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 5,974 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Condition Clear all
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

NCT04817241
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin, Decitabine and Cedazuridine, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gait Metric Validation of the Cionic Neural Sleeve

NCT06503354
View directory record Official record
Conditions
Validation Study
Interventions
Neural Sleeve and Zeno walkway
Device
Lead sponsor
Cionic, Inc.
Industry
Eligibility
22 Years to 64 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional

Serrantor OCT Study

NCT06434194
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Serranator PTA Serration Catheter, PTA (Standard of Care)
Device · Drug
Lead sponsor
Cagent Vascular LLC
Industry
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 30, 2026, 3:14 AM EDT
Withdrawn Phase 3 Interventional

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

NCT03066466
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
Atorvastatin, Methotrexate, Tacrolimus
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 30, 2026, 3:14 AM EDT
Terminated Phase 1 Interventional

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

NCT03511222
View directory record Official record
Conditions
Solid Tumor, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Vorolanib, Nivolumab, Pembrolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Prompt Diagnosis and Treatment of Subclinical Seizures After Cardiac Arrest

NCT02458820
View directory record Official record
Conditions
Heart Arrest, Seizures
Interventions
DSA EEG
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Days and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional

The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans Aged 55+. It Combines Pharmacist Counseling and CHW Support to Improve Blood Pressure Control in Hypertension Management.

NCT07413159
View directory record Official record
Conditions
Hypertension
Interventions
Pharmacists Only (Control Group), Combined Intervention (Pharmacists + CHW Interventions)
Other
Lead sponsor
Texas Southern University
Other
Eligibility
55 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Phase 1 Interventional

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

NCT06737380
View directory record Official record
Conditions
SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
Interventions
Physical examination, Electrocardiogram, SF-36 questionnaire, Clinical laboratory evaluations - Serology, Clinical laboratory evaluations - Biochemistry, Clinical laboratory evaluations - Hematology, Pregnancy Test, Urinalysis, SLE activity evaluation, SLE biomarker profiling, Cytokines and chemokine profiling, single dose of UC-MSCs, PROMIS instruments
Diagnostic Test · Other · Biological
Lead sponsor
LiveKidney.Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia

NCT05892770
View directory record Official record
Conditions
Spasmodic Dysphonia
Interventions
Zinc gluconate supplement, Botulinum toxin type A
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Active, not recruiting Phase 3 Interventional

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

NCT03712605
View directory record Official record
Conditions
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Best Practice, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Radiation Therapy
Other · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
552
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

NCT04104022
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Prolonged Exposure Therapy, Attendance-based monetary incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379
View directory record Official record
Conditions
Hypogammaglobulinemia, Congenital Heart Disease
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 6 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 30, 2026, 3:14 AM EDT
Active, not recruiting Phase 2 Interventional

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

NCT04397003
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device, Peripheral blood draws
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Suspended Not applicable Interventional

Intermittent Theta Burst Stimulation for MDD

NCT02506127
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Neuronetics XPLOR system
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
22 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family-Focused CBT Skills App and Standard Self Help Options for Childhood Anxiety

NCT03269370
View directory record Official record
Conditions
Anxiety Disorders, Childhood Mental Disorder, Anxiety
Interventions
Anchors Away, Parent Enhanced Anchors Away, Self-Help E-Book
Behavioral
Lead sponsor
Kansas City Center for Anxiety Treatment, P.A.
Industry
Eligibility
6 Years to 11 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Acceptance and Commitment Therapy Principles for Diabetes Prevention

NCT05260983
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2, Diabetes, Diabetes type2
Interventions
Diabetes Prevention Education and Acceptance and Commitment Therapy, Diabetes Prevention Education Only
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 30, 2026, 3:14 AM EDT
Active, not recruiting Not applicable Interventional

Psoriatic Arthritis D2P Screening

NCT04110522
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Direct to patient PsA Screening Questionnaire
Other
Lead sponsor
Jessica Walsh
Other
Eligibility
18 Years and older
Enrollment
18,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting No phase listed Observational

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

NCT05584722
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 80 Years
Enrollment
150 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Withdrawn Phase 1 Interventional

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

NCT06137651
View directory record Official record
Conditions
Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Radiation Therapy, Resection, Trotabresib, Vinorelbine
Procedure · Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

NCT01449370
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
TAK-117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Epoetin Hospira Arm, Standard of Care Arm, IV Iron
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
42
States / cities
Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

NCT06896162
View directory record Official record
Conditions
Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions
Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Leukemia

NCT02071927
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Interventions
CB-839, CB-Aza
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Applying pGz in Mitochondrial Disease

NCT05569122
View directory record Official record
Conditions
Mitochondrial Myopathies, Mitochondrial Diseases
Interventions
Cardiopulmonary Exercise Testing, pGz Bed, Gentle Jogger, Exercise Pedal, Lumason® contrast agent
Diagnostic Test · Device · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 3:14 AM EDT